Autres langues AcuCort AB

Actions

ACUC

SE0009695927

Pharmacies

Cours en clôture SPOTLIGHT STOCK MARKET AB 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,4980 ^SEK	+0,20%		+0,20%	-17,00%

05/10	Acucort : « Le risque réglementaire a nettement diminué » – le directeur général	FW
05/10	AcuCort va procéder à une augmentation de capital pour obtenir l’autorisation réglementaire américaine de Zeqmelit	MT

Autres langues

06/10	AcuCort's CEO Jonas Jönmark to take part in live broadcast on rights issue and US expansion
06/10	AcuCort invites investors to Capital Markets Day on 13 October
05/10	AcuCort to Raise Equity in Bid to Secure US Regulatory Approval for Zeqmelit
05/10	AcuCort AB resolves on a rights issue of units of initially approximately SEK 70.3 million to finance continued efforts towards FDA approval and accelerate commercialization, and raises a bridge loan
28/09	AcuCort publishes September 2026 newsletter
16/09	AcuCort Secures Funds from Swedish Regional Body for US Expansion
16/09	AcuCort awarded funding from Region Skåne to support its US expansion
16/09	AcuCort AB Receives Funding From Region Skåne To Support US Expansion
07/09	AcuCort AB Registers Zeqmelit as Trade Mark in Ukraine
07/09	AcuCort : product Zeqmelit® registered as a trade mark in Ukraine
07/09	AcuCort's product Zeqmelit® registered as a trade mark in Ukraine
01/09	AcuCort's warrant programme fully subscribed - key personnel to become shareholders in the company
31/08	AcuCort has published August 2026 newsletter
26/08	AcuCort: AcuCort study on patient preferences published in peer-reviewed scientific journal
26/08	AcuCort study on patient preferences published in peer-reviewed scientific journal
24/08	AcuCort: AcuCort appoints Carl Frisk as Strategic Alliance Manager
24/08	AcuCort appoints Carl Frisk as Strategic Alliance Manager
19/08	AcuCort AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
11/08	AcuCort : first Phase IV study is now published
11/08	AcuCort: AcuCort’s first Phase IV study is now published
11/08	AcuCort's first Phase IV study is now published
11/08	Acucort Publishes Results from Phase Iv Study with Zeqmelit Oral Film
27/07	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission
27/07	AcuCort Renews US FDA Small Business Waiver for New Drug Applications
27/07	AcuCort : granted renewed FDA Small Business Waiver – Important milestone ahead of planned NDA submission in 2026